<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110591</url>
  </required_header>
  <id_info>
    <org_study_id>5R44AI046871-04</org_study_id>
    <secondary_id>PRO140-1101</secondary_id>
    <nct_id>NCT00110591</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double Blind, Placebo Controlled, Single-Dose, Rising Dose Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO 140 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoDyn, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoDyn, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and tolerability of PRO 140, an
      investigational anti-HIV drug, administered via intravenous infusion.

      Study hypothesis: Single intravenous doses of PRO 140 can be safely administered to humans
      and will result in measurable concentrations of the product in serum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRO 140 is a man-made monoclonal antibody to the chemokine receptor CCR5, which serves as a
      co-receptor for HIV. In numerous preclinical models of HIV infection, PRO 140 broadly and
      potently blocks CCR5-mediated HIV entry without blocking the natural activity of CCR5. PRO
      140 is being developed for therapy of HIV infected individuals. The purpose of this study is
      to evaluate the safety and tolerability of PRO 140 in HIV uninfected male volunteers. The
      pharmacokinetics and pharmacodynamics of PRO 140 will also be assessed in this study.

      Participants in this study will be randomly assigned to receive a single dose of one of
      several possible doses of PRO 140 or placebo. Participants will remain in the clinic for
      observation and evaluation for 24 hours after the single-dose administration. Follow-up
      visits will occur at 2, 3, 5, 7, 10, 14, 28, 42, and 60 days post-treatment. Physical exams,
      electrocardiograms (ECGs), vital signs measurement, adverse event reporting, and blood and
      urine collection will occur at most visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of PRO 140</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous placebo for PRO 140</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO 140 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg/kg PRO 140 by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO 140 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg PRO 140 by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO 140 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg/kg PRO 140 by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO 140 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0 mg/kg PRO 140 by intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO 140</intervention_name>
    <description>Monoclonal antibody to CCR5</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>PRO 140 dose 1</arm_group_label>
    <arm_group_label>PRO 140 dose 2</arm_group_label>
    <arm_group_label>PRO 140 dose 3</arm_group_label>
    <arm_group_label>PRO 140 dose 4</arm_group_label>
    <other_name>Humanized monoclonal antibody to CCR5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not more than 20% below or 20% above ideal weight for height and estimated frame size

          -  Good health, with no clinically significant abnormal findings on the physical
             examination, medical history, or laboratory tests

        Exclusion Criteria:

          -  History of clinically significant disease

          -  History of clinically significant allergies, including drug allergy

          -  Participated in another clinical trial within the 3 months prior to study entry

          -  HIV infected

          -  Hepatitis B or C virus infected

          -  Active significant infection

          -  Prior exposure, allergy, or known hypersensitivity to PRO 140
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Olson, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vice President, Clinical Research, Progenics Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2005</study_first_submitted>
  <study_first_submitted_qc>May 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2005</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>HIV Antibodies</mesh_term>
    <mesh_term>PRO-140 monoclonal antibody</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

